Recent updates and perspectives on approaches for the development of vaccines against visceral leishmaniasis

Abstract: Visceral leishmaniasis (VL) is one of the most important tropical diseases worldwide. Although chemotherapy has been widely used to treat this disease, problems related to the development of parasite resistance and side effects associated with the compounds used have been noted. Hence, alt...

Full description

Bibliographic Details
Published in:Revista da Sociedade Brasileira de Medicina Tropical
Main Authors: Mariana Costa Duarte, Daniela Pagliara Lage, Vívian Tamietti Martins, Miguel Angel Chávez-Fumagalli, Bruno Mendes Roatt, Daniel Menezes-Souza, Luiz Ricardo Goulart, Manuel Soto, Carlos Alberto Pereira Tavares, Eduardo Antonio Ferraz Coelho
Format: Article in Journal/Newspaper
Language:English
Published: Sociedade Brasileira de Medicina Tropical (SBMT)
Subjects:
Vaccine. Visceral leishmaniasis
Recombinant proteins
Immuno-proteomic approach
Hypothetical proteins
Arctic medicine. Tropical medicine
RC955-962
Arctic
Online Access:https://doi.org/10.1590/0037-8682-0120-2016
https://doaj.org/article/94ef84e8c4eb4d409ee254ac9a4b56ee
Description
Summary:Abstract: Visceral leishmaniasis (VL) is one of the most important tropical diseases worldwide. Although chemotherapy has been widely used to treat this disease, problems related to the development of parasite resistance and side effects associated with the compounds used have been noted. Hence, alternative approaches for VL control are desirable. Some methods, such as vector control and culling of infected dogs, are insufficiently effective, with the latter not ethically recommended. The development of vaccines to prevent VL is a feasible and desirable measure for disease control; for example, some vaccines designed to protect dogs against VL have recently been brought to market. These vaccines are based on the combination of parasite fractions or recombinant proteins with adjuvants that are able to induce cellular immune responses; however, their partial efficacy and the absence of a vaccine to protect against human leishmaniasis underline the need for characterization of new vaccine candidates. This review presents recent advances in control measures for VL based on vaccine development, describing extensively studied antigens, as well as new antigenic proteins recently identified using immuno-proteomic techniques.

Similar Items